Online citations, reference lists, and bibliographies.

Modern Management Of Malignant Pleural Mesothelioma

S. Patel, J. Dowell
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a deadly disease that produces a significant worldwide health care burden. The majority of cases are associated with prior asbestos exposure, but recent studies have identified a possible genetic predisposition in a minority of patients. Historically, obtaining a pathologic diagnosis of MPM was challenging, but with current pathological techniques, a secure diagnosis is possible in the majority of patients. Curative therapy for MPM remains elusive, and the primary treatment option for fit patients is platinum-based chemotherapy. Encouraging recent reports suggest that there may be a benefit to the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in MPM. Selected patients may be considered for aggressive surgical approaches, but there is considerable controversy regarding the true benefit of surgery and multimodality therapy in this disease.
This paper references
10.2147/lctt
Lung Cancer: Targets and Therapy
Matthew A. Gubens (2010)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/j.hlc.2010.11.045
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2011)
10.1016/J.RMED.2006.10.018
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
A. Scherpereel (2007)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
10.1200/JCO.2015.33.15_SUPPL.7564
Confirmation of high prevalence of BAP1 inactivation in mesothelioma.
Andrea Cercek (2015)
10.1097/00063198-200007000-00003
Management of malignant pleural mesothelioma: a critical review
Y. Lee (2000)
Guidelines of the ERS/ESTS for management of malignant pleural mesothelioma
A Scherpereel (2010)
BTS statement of malignant mesothelioma in the UK
A Scherpereel (2007)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1002/dc.23271
Guidelines for the cytopathologic diagnosis of epithelioid and mixed‐type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
A. Hjerpe (2015)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM)
EW Alley (2015)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch
Epidemiology Surveillance (1973)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.18632/ONCOTARGET.4414
Distinctive clinical characteristics of malignant mesothelioma in young patients
A. Thomas (2015)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
British Thoracic Society Standards of Care Committee
S. Blumenthal (2014)
10.1093/ANNONC/MDM027
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
C. Manegold (2007)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1093/annonc/mdn083
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
R. Stahel (2008)
Speaking Society for Chest Medicine (SPLF) Experts Group. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma
A Scherpereel (2007)
10.1200/JCO.2013.49.9616
Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.
L. Chirieac (2013)
Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated? Interact Cardiovasc Thorac Surg. 2011;13:66–69
M Nagendran (2011)
Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Medical thoracoscopy vs CT scanguided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions
M Metintas
Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/lung-cancer-targets--therapy-journal
10.1510/icvts.2011.267252
Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated?
Myura Nagendran (2011)
10.1183/09031936.98.11010213
Thoracoscopy--state of the art.
R. Loddenkemper (1998)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1016/J.HOC.2005.09.009
Prognostic factors for mesothelioma.
J. Steele (2005)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1002/cncy.21563
Comments on the recently published “Guidelines for the cytopathologic diagnosis of epithelioid and mixed‐type malignant mesothelioma”
A. Hjerpe (2015)
10.1016/j.athoracsur.2005.06.014
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
Giovanni Luca Ceresoli (2010)
French Speaking Society for Chest Medicine (SPLF) Experts Group. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma
A Scherpereel (2007)
10.1258/jrsm.2010.100345
A systematic review of lung-sparing extirpative surgery for pleural mesothelioma
Elaine S Teh (2011)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1016/S0140-6736(14)60418-9
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
10.5152/pb.2011.16
EXTRA-PLEURAL PNEUMONECTOMY VERSUS NO EXTRA-PLEURAL
Emine Kamiloğlu (2011)
10.1097/00063198-199907000-00015
Pleural mesothelioma.
P. Astoul (1999)
10.2105/AJPH.2012.300928
Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries.
H. Gibb (2013)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
Curr Opin Pulm Med
P Astoul (1999)
10.1378/chest.102.4.1110
The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura.
H. Beauchamp (1992)
10.3816/CLC.2010.n.005
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
10.1002/jcp.22724
Malignant mesothelioma: Facts, Myths, and Hypotheses
M. Carbone (2012)
10.1016/J.THORSURG.2004.06.006
Patterns of failure following surgical resection for malignant pleural mesothelioma.
P. Jänne (2004)
10.1183/09031936.00184308
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
A. Brunelli (2009)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1245/s10434-011-1728-x
Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
Mbbs Christopher Cao BSc (2011)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1378/chest.09-0884
Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
M. Metintas (2010)
10.3978/j.issn.2305-5839.2015.07.03
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Weiquan Zhang (2015)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1111/cyt.12250
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed‐Type Malignant Mesothelioma: a secondary publication
A. Hjerpe (2015)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1378/CHEST.120.6.1798
Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma.
R. F. Adams (2001)
10.1097/JTO.0000000000000078
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
B. Cho (2014)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.1136/oem.2005.023200
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1016/S0140-6736(03)13079-6
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial
N. Maskell (2003)
10.1378/CHEST.129.6.1549
The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions.
B. Chakrabarti (2006)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1158/1538-7445.am2015-2752
Abstract 2752: Prevalence of BAP1 germline mutations in asbestos-exposed malignant mesothelioma cases and controls
Mitchell Cheung (2015)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Jonathan E. Dowell (2012)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)



This paper is referenced by
10.1101/2020.05.13.20087189
Trimodality Treatment in Malignant Pleural Mesothelioma: An Ordeal or The Real Deal?
Naveen Mummudi (2020)
10.1111/cas.13871
Establishment and characterization of CRISPR/Cas9‐mediated NF2 −/− human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma
M. Wahiduzzaman (2019)
10.1513/AnnalsATS.201702-185CME
ATS Core Curriculum 2017: Part IV. Adult Pulmonary Medicine
Gaëtane C Michaud (2017)
10.21037/shc.2018.05.05
Video-assisted thoracoscopic surgery in the management of mesothelioma
J. Ali (2018)
10.21037/jtd.2017.10.19
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
M. Cinausero (2018)
10.11648/j.ijcts.20170306.14
Malignant Pleural Mesothelioma: An Update on the Role of Surgery
Maria Kalliopi Konstantinidou (2017)
10.17352/JNNSD.000016
Metastic Mesothelioma to the Brain: A Potential Differential Diagnosic Challenge
Dalwadi Vd (2017)
10.3390/ijms21145165
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
M. Bonelli (2020)
Risk factors and biomarkers for malignant mesothelioma
Vasiliki Panou (2019)
10.1016/j.rmcr.2018.02.006
Malignant mesothelioma presenting as recurrent hydro-pneumothorax: An atypical case presentation and literature review☆
Nadia Sattar (2018)
10.1002/ccr3.1775
Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
F. Grosso (2018)
10.1007/s12055-017-0606-y
Surgery for mesothelioma: the evidence base and a pragmatic approach to surgical treatment
Vasudev Baburaya Pai (2017)
10.1007/978-3-319-93055-8
Thoracic Ultrasound and Integrated Imaging
F. Feletti (2020)
10.1080/0284186X.2018.1532599
Malignant pleural mesothelioma in Finland: regional and gender variation
Sanna Laaksonen (2019)
10.21037/tlcr.2017.06.01
Novel systemic therapy against malignant pleural mesothelioma.
M. R. Mancuso (2017)
A population-based survival analysis of mesothelioma and smoking in Appalachian and Non-Appalachian Kentucky
P. V. Wie (2017)
10.1371/journal.pone.0205018
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
Raffaella Cincinelli (2018)
10.4172/2472-1247.1000134
The Role of Immunotherapy in Malignant Mesothelioma
Kastelik Ja (2018)
10.1016/j.critrevonc.2019.102815
Emerging therapies in malignant pleural mesothelioma.
Marika Cinausero (2019)
10.3390/ijms21124327
Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review
V. Panou (2020)
Semantic Scholar Logo Some data provided by SemanticScholar